Delpor

Delpor is a private, clinical-stage biotech company pioneering once-yearly subcutaneous implant therapies for chronic diseases, with a primary focus on CNS disorders. Its proprietary, passive (non-mechanical) implant technology aims to improve patient adherence, safety, and efficacy by maintaining steady drug levels within a therapeutic window for up to a year. The company's most advanced program is a risperidone implant for schizophrenia, which has completed a Phase 1b/2a study, and it has also initiated a Phase 1 trial for a naltrexone implant for opioid addiction. Delpor's business model is centered on developing and commercializing novel therapeutic products enabled by its delivery platform.

Proprietary passive (non-mechanical) subcutaneous implant technology enabling zero-order, sustained release of drugs (small molecules and potentially biologics) for 6-12 months. Key features include full reversibility (implant removal), a smooth PK profile within the therapeutic window, no need for treatment initiation dosing, and a 1-day washout period.

Delpor competes in the long-acting drug delivery space, primarily against developers of long-acting injectables (LAIs) for schizophrenia (e.g., from Johnson & Johnson, Otsuka/Lundbeck, Alkermes) and OUD (Alkermes' Vivitrol). Its key differentiators are the once-yearly duration, zero-order release kinetics, and full reversibility, which are not features of current market-leading LAIs. It may also face future competition from other implant or novel delivery technologies in development.